Advanced searches left 3/3

Valproic Acid - Europe PMC

Summarized by Plex Scholar
Last Updated: 06 August 2022

* If you want to update the article please login/register

Effect of long-term valproic acid therapy on lipid profiles in paediatric patients with epilepsy: a meta-analysis

Despite the fact that valproic acid may have been involved in weight gain, the effects of VPA therapy on lipid profiles are uncertain. This study was conducted to investigate the effect of VPA therapy on serum lipid profiles in children with epilepsy. VPA therapy has been shown to have a dramatic decline in total cholesterol and low-density lipoprotein cholesterol levels as a result. Significance In conclusion, this meta-analysis shows that VPA therapy results in a decrease in total cholesterol and low-density lipoprotein cholesterol.

Source link: https://europepmc.org/article/MED/35816100


Potential of the zebrafish (Danio rerio) embryo test to discriminate between chemicals of similar molecular structure-a study with valproic acid and 14 of its analogues.

Valproic acid is a commonly used antiepileptic drug and a well-known pediatric hepatotoxic agent. Alternative testing strategies are being created in an attempt to minimize mammalian testing while also ensuring the safety of toxicity testing of new industrial chemicals and drugs. To this end, the ability of the zebrafish embryo to distinguish between valproic acid and 14 analogues was investigated by exposing zebrafish embryos for 120 h post fertilization in the extended version of the fish embryo acute toxicity test, as well as testing liver histology to determine the relationship between liver function and each compound's molecular structure. The structure-activity relationship derived was comparable not only to human HepG2 cells but also to experimental rat and mouse data, although histological examination of zebrafish liver did not identify steatosis as the prevalent adverse effect present in human and mice.

Source link: https://europepmc.org/article/MED/35920856


Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis.

The aim of this research was to conduct a meta-analysis of studies looking at blood ammonia and carnitine in patients treated with VPA. Methods We used database searches to locate studies that looked at blood samples of ammonia and carnitine in patients treated with VPA. Results According to the cross-sectional comparisons, the blood ammonia level in the VPA group was much higher than that in the non-VPA group. The blood carnitine level in the VPA group was significantly lower in comparison to that in the non-VPA group. The blood VPA level was moderately related to blood ammonia and blood free carnitine levels in the random effects model, according to the meta-analysis of correlation coefficients. Conclusion Although the correlation between ammonia and free carnitine levels in blood was high, clinicians did not have the ability to determine free carnitine levels from the ammonia study findings.

Source link: https://europepmc.org/article/MED/35879038


Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?

For augmentation therapy in treatment-resistant schizophrenia, the combination of valproic acid and clozapine is often used for augmentation therapy. The aim of this study is to investigate the differences between patients treated with CLZ and patients treated with CLZ plus VPA. The study was based on plasma samples from CLZ and CLZ plus VPA treated patients exposed to routine therapeutic drug testing, including clinical information, smoking status, daily dose of CLZ and VPA, concomitant medications, albumin, and renal and hepatic function. Patients with UGT2B10 GG genotype showed lower NCLZ plasma values and C/D NCLZ, as well as a higher CLZ/NCLZ ratio relative to patients with UGT2B10 GG genotype. The CLZ/NCLZ ratio is weakened by reduced NCLZ values and possibly with an elevated risk of neutropenia, according to cigarettes, the presence of UGT2B10 GT genotype, and low albumin levels, mainly due to reduced NCLZ values and possibly with an elevated risk of neutropenia.

Source link: https://europepmc.org/article/MED/35853541


The effects of valproic acid on skin healing: experimental study in rats.

Purpose: To explore the skin healing process, the skin healing process is improved by valproic acid, an epigenetic drug. Methods Sixty male Wistar rats were divided into two groups: the experimental group was treated with VPA; and the control, with 0. 9% sodium chloride gavage. In three hours, skin healing was examined, determining the inflammatory response and its severity, angiogenesis, collagen I and III, and myofibroblasts. In the treated group, collagen I was greater than in the control at the three times and collagen III.

Source link: https://europepmc.org/article/MED/35857935


Alterations in the intrinsic discharge activity of CA1 pyramidal neurons associated with possible changes in the NADPH diaphorase activity in a rat model of autism induced by prenatal exposure to valproic acid.

Although new evidence reveals that autism-like behavior in animal models results in abnormal neuronal excitability, pediatric neuronal excitability, the effect of autism on neuronal properties is also an important topic. The hot plate response latency was reduced by a significant increase thanks to VPA exposure, according to the researchers. Along with these behavioral changes, neurons from VPA-exposed animals displayed altered excitability characteristics in response to depolarizing current injections relative to control neurons. These changes in the evoked electrophysiological characteristics were followed by intrinsic hyperexcitability and lower spike-frequency responses, as well as a significant increase in the number of NADPH-diaphorase stained neurons in the VPA-exposed rats' hippocampal CA1 region. In a rat model of autism-like, abnormal nociception and recognition memory is linked to improvements in the neuronal responsiveness and recognition pathway.

Source link: https://europepmc.org/article/MED/35841982


Therapeutic Potential of Valproic Acid for Postviral Olfactory Dysfunction: A Single-Arm Pilot Study.

Objectives Although some patients with postviral olfactory dysfunction recover spontaneously, several others are left with the same degree of smell loss and there are no approved medications for the treatment of patients with PVOD. Despite the fact that the mean duration of olfactory dysfunction in this study was 11. 5 months, both odor recognition threshold and odor detection threshold scores increased by a significant 4 weeks after treatment initiation relative to the pre-treatment threshold scores. The olfactory cure rates of patients with PVOD were both 77. 8% at 12 weeks and 24 weeks of VPA therapy, and the olfactory cure rates at 12 weeks and 24 weeks of VPA therapy were 43. 3% and 44 percent, respectively. In the future, the effects of VPA therapy for PVOD patients should be investigated with a controlled research approach.

Source link: https://europepmc.org/article/MED/35833237


Changes of cerebellar cortex in a valproic acid-induced rat model of autism.

In this research, 32 male Sprague-Dawley rats were used in total to investigate the effects of valproic acid on rat cerebellum. Granule cells in experimental groups of rats' cerebellum increased, but the numerical density of Purkinje cells decreased. Moreover, the granule cells had a smaller mean nuclear diameter in one of the experimental groups, as well as the Purkinje cells had larger mean nuclear diameter in one of the experimental groups, compared to those in the comparison group.

Source link: https://europepmc.org/article/MED/35831992


The Antiepileptic Drug and Toxic Teratogen Valproic Acid Alters Microglia in an Environmental Mouse Model of Autism.

Valproic acid is a multi-target drug commonly used to treat epilepsy. Hence, we found the effect of prenatal exposure to VPA on microglial counts in early postnatal brain development in this study. In male mice, prenatal exposure to VPA leads to a significant decrease in the number of microglia in the primary motor cortex during early postnatal brain development, particularly at postnatal day 6 and postnatal day ten. The early microglial decrease in the VPA model coincides with normal cortical syntegenesis and is significant because it may have a role in ASD's poor connectivity.

Source link: https://europepmc.org/article/MED/35878284

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions